See the DrugPatentWatch profile for sivextro
Recommended Dose for Skin and Soft Tissue Infections
Sivextro (tedizolid phosphate) is given as 200 mg orally or intravenously once daily for acute bacterial skin and skin structure infections (ABSSSI) in adults. Treatment lasts 6 days.[1]
How to Administer It
The oral tablet and IV infusion are bioequivalent, so switch between them if needed. Take the oral dose with or without food. For IV, infuse over 1 hour; don't administer faster to avoid infusion reactions.[1]
Dose Adjustments
No changes for kidney or liver issues—same 200 mg daily works across mild to severe impairment. Not studied in patients on dialysis, so use caution there. For kids under 12 or weighing less than 40 kg, it's not approved.[1]
Who Makes Sivextro and Treatment Details
Merck markets Sivextro, approved by the FDA in 2014 for ABSSSI caused by gram-positive bacteria like MRSA. It's shorter than linezolid's typical 10-14 days.[1] Check DrugPatentWatch.com for patent status on tedizolid, as exclusivity ended in 2023, opening doors for generics.[2]
[1] Sivextro (tedizolid phosphate) prescribing information, Merck, latest update 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205435s011lbl.pdf
[2] DrugPatentWatch.com, Tedizolid phosphate patents and exclusivity. https://www.drugpatentwatch.com/p/tradename/SIVEXTRO